About Us

About Adagene

Adagene is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. With the mission to create a positive global impact with its technology, Adagene seeks to establish technology-driven discovery partnerships with the world’s leading pharmaceutical and biotechnology companies and build therapeutic pipelines for future licensing and development.

The Smart Antibody Technology strikes the fine balance between Mother Nature and human design, resulting in antibodies with enhanced safety and potency profiles. It is through this unique harmonization of natural repertoires with targeted synthetic designs that leads to the development of superior bio-therapeutics. The intrinsic limitation of current antibody technology fails in its ability to create antibodies with unprecedented precision, speed, and effectiveness. Through Smart Antibody Technology, Adagene seeks to transform the precision for antibody generation, engineering and development, with tailor-made attributes for therapeutic, diagnostic, and research applications.

Why Adagene

Adagene is founded on the principal that better therapeutics find their root in intelligent design and engineering blended with the natural tendency of nature to adapt and change to suit its purpose.
This principal is not new. It is rooted in the teachings of the past.

"It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the most adaptable to change."

-- Charles Darwin, Origin of Species

“物竞天择,适者生存”
"Natural selection, survival of the fittest."

-- 严复《天演论》
-- Yan Fu

Why in Suzhou

Suzhou blends history with innovation setting a path for the future.

Suzhou is one of the oldest cities in China, laying claim to over 2,500 years of rich history. The city is most famous for its man-made gardens, whose architects sought to embody these structures with a fine balance of the artificial and natural. The Smart Antibody Technology strives to mirror such an architectural principle in antibody engineering by utilizing a unique harmonization of natural repertoires with targeted synthetic designs.

"The same spirit should prevail when we set out to apply the smart antibody technology in the creation of the antibody."

Peter (Peizhi) Luo
Founder and CEO

Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. He utilizes a multi-disciplinary approach to his work, combining methods from experimental and computational biology, chemistry, and physics.

Prior to this, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Before the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. During Dr. Luo’s time at Merck, he designed and built the antibody libraries and engineering platforms that propelled the discovery of Merck’s novel biologics.  He received two Merck Special Achievement Awards for his leadership and scientific contribution. Before his work at Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Through his work at Stanford, Dr. Luo discovered the fundamental mechanisms of protein folding and stability concerning the solvation of peptide backbone by cosolvents and amino acid side-chains.

Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

Max N. Dawson
VP of Business Development

Max N. Dawson is the Vice President of business development and head of licensing at Adagene. He has extensive experience in partnering and strategic planning, and is focused on fostering synergistic relationship in the pharmaceutical and biotech industry for the purpose of advancing human healthcare.

Prior to joining Adagene, Max consulted for private and venture backed technology companies in the US and Asia, advising on corporate strategy and licensing at the executive and board level. He also spent several years running the licensing division at Dyax Corp., where he participated in over 30 transactions and debt financings. Prior to this, Max has held finance positions at both Vertex Pharmaceuticals and Merck KGaA.

Before his roles in finance and business development, Max was a bench scientist in the protein biochemistry department at Vertex Pharmaceuticals.

Max holds an M.B.A from the F.W. Olin Graduate School of Business at Babson College, where he has guest lectured on marketing and biotechnology. He completed his undergraduate work at Bates College.

Felix (Fangyong) Du
VP of Technology Development

Dr. Felix (Fangyong) Du is the Vice President of Technology Development at Adagene. He has over 20 years of experience in biological research and discovery, and has published numerous peer-reviewed articles, including original articles in world-renowned scientific journals such as Nature and Science. His discoveries were featured on the cover of Nature and critically reviewed with high praise by prominent scientists in the field.

Before joining Adagene, Dr. Du worked at Affomix, a biotech startup by Yale professors that specializes in high throughput discovery of antibodies against human proteome. He created an innovative technology platform for high throughput preparation and oriented presentation of antigens. After acquisition of Affomix by Illumina Inc., Dr. Du continued to develop new technologies in protein and nucleic acid chemistry.

Dr. Du completed his postdoctoral research with Dr. Jorge Galan at Yale University, received his Ph.D. under the guidance of Dr. Alex Varshavsky at the California Institute of Technology, and obtained his B.S. and M.S. degrees from Peking University.

Yan Li
VP of Bioinformatics and IT

Ms. Yan Li is the Vice President of Bioinformatics and Information Technology at Adagene. She has over 15 years of experience in software development, with more than 10 years focused on the development of informatics software tools for antibody library design and analysis.

Prior to joining Adagene, Ms. Li served as the Senior Software Engineer and Applications Scientist at Abmaxis from Nov 2001 to May 2006. She developed the software platform for the company’s proprietary AISIM technology, and designed many antibody libraries for in-house pipeline development and business partners. Following the acquisition of Abmaxis by Merck & Co, Ms. Li worked at Merck from May 2006 to Dec 2010. She received the Merck Award for Excellence in "Innovative Technologies” with the team, and a Special Award for her contribution.

Before her time at Abmaxis, Ms. Li served as a software engineer at Easyware Software, and also as a system analyst and product manager at Singapore Telecom.

Ms. Li received her BSE in Information Science from East China University of Science and Technology, and her M.B.A. from Santa Clara University with Beta Gamma Sigma honor. She is an inventor of many US and international patents.

Kristine (Xiaohong) She
VP of Operations

Ms. Kristine (Xiaohong) She serves as the Vice President of Operations at Adagene. She has over 20 years of laboratory experience in America’s most renown laboratories, completing multiple projects in molecular biology and immunology at the labs of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran’s Hospital, and cloning and functional screening of cDNA libraries at Caltech. Her work has been published in Nature, Science, Biotechnology, among many other notable publications. From these projects, Ms. She has gained extensive operational and management experience, as she often led her coworkers in laboratory and experimental work.

Ms. She received her M.S. degree from the Institute of Microbiology of the Chinese Academy of Sciences, and her B.S. degree from Wuhan University.

Daniel Auerbach Biography
Managing Partner, Asia

Daniel Auerbach is the Managing Partner of Eight Roads Capital Advisors (Hong Kong) Limited, the Asia Pacific Private Equity and Venture investing arm of FIL Limited (formerly Fidelity International Ltd), an affiliate of one of the World’s largest, independent, privately held money management firms.

Mr. Auerbach has held this role since 1994, representing a significant component of his 30 years in Asia as an early pioneer and leader in the

Development of Asia’s Private Equity industry. Through his business involvement Mr. Auerbach is associated with the establishment of some of the region’s most successful independent businesses in the areas of the internet, IT out-sourcing, software, media, telecommunications, education, business-process outsourcing, infrastructure, health care services, bio-chemistry research services, bio-technology and bio-pharma development and distribution. Mr. Auerbach has held key board roles with a multitude of companies, including the Alibaba Group, Wuxi Pharmatech, AsiaInfo, Asia Renal Care and several others. He continues to serve on a number of Boards of Asia’s leading emerging businesses. Mr. Auerbach is a member of Fidelity’s Senior Leadership throughout Asia Pacific.

Prior to 1994 for a period spanning over 7 years, Mr. Auerbach was a Partner at Arral and Partners, one of Asia’s first independent private equity firms, based in Hong Kong. Among other things Arral and Partners was the founding investor in the Aman Resorts Hotel Group, where Mr. Auerbach played a key role in its global development since its establishment in 1987. From 1980-1985 Mr. Auerbach was based in Boston working at Fidelity as an equity analyst and portfolio management assistant to Peter Lynch, the manager of the Fidelity Magellan Fund.

Apart from his business activities, Mr. Auerbach is a member of various international and local businesses, philanthropic and civic organisations. He is a Trustee of Hong Kong‘s World Wildlife Fund; A Trustee of the Hong Kong Plastic Oceans Foundation; A member of the Board of Overseers at the Morningside College, Asia’s first liberal arts college based in Hong Kong; A member of the Presidential Advisory Board of the Berklee College of Music in Boston. Mr. Auerbach also plays a primary role in leading a multitude of initiatives on behalf of the Fidelity Charitable Foundations.

In 2000, Mr. Auerbach was nominated by the World Economic Forum as one of its Young Global Leaders.

Mr. Auerbach holds a B.A from Dartmouth College (1980) in Economics and Foreign Languages and an M.B.A. from The Harvard Business School in Boston. Mr. Auerbach lives in Hong Kong.

Thomas R. Beck, M.D.
Executive Partner, F-Prime Capital

Tom joined F-Prime Capital as an Executive Partner in September, 2007. Most recently, he served as President, Chief Operating Officer at Dyax Corp. Prior to that, he held positions at UCB Pharma (Corporate Vice President, Director of Global Research and Development), CytoMed, Inc (Chairman and Chief Executive Officer), and Enzytech, Inc (President). He began his industry career at Smith Kline and French, where he held positions in both clinical development and business development.

Dr. Beck is Board-certified in Internal Medicine and Nephrology and was Assistant Professor of Medicine at Temple University School of Medicine prior to joining the pharmaceutical industry. He received his B.S. degree from Yale University and his M.D. from Cornell University.

Since joining F-Prime Capital, Dr. Beck has been on the boards of NeuroTherapeutics Pharma, Topaz Pharmaceuticals, Vicept Therapeutics, and Dimension Therapeutics. He is currently on the boards of Mersana Therapeutics, Adagene, Ltd., and Symbiomix Therapeutics, and is an observer at Aclaris Therapeutics. He has been CEO of Topaz Pharmaceuticals and Dimension Therapeutics. He currently is Head, Research and Development at Symbiomix.

Ge Li, Ph.D.
Chairman and Chief Executive Officer, Wuxi PharmaTech

Dr. Ge Li is the Founder, Chairman and Chief Executive Officer of WuXi PharmaTech (NYSE: WX), a leading open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries. Dr. Li studied at Peking University as an undergraduate and received his Ph.D. in Organic Chemistry from Columbia University. He began his industry career in 1993 as one of the founding scientists at Pharmacopeia, Inc. (NASDAQ: PCOP). In 2000, Dr. Li moved back to Shanghai to found WuXi PharmaTech and has since been its Chairman and CEO. Under Dr. Li’s leadership, WuXi has grown from 4 founders and a single laboratory of 7,000 square feet in Year 2000 to a global operation with over 10,000 employees and facilities totaling 5 million square feet for world-class research, development and manufacturing to help advance some of the most innovative healthcare products for patients around the world. Dr. Li's entrepreneurship and achievements have won him numerous prestigious awards and honors, including “The 25 Most Influential People in Biopharma in 2015”, “Forbes 25 Notable Chinese-Americans”, “The 60 Most Influential People during 60 Years Pharmaceutical Development in China”, “Ernst & Young Entrepreneur of the Year China Award”, and “The Boston Biotech Chief Executive Offcers Conference Life Achievement Award”.

Peter (Peizhi) Luo, Ph.D.
Founder and CEO, Adagene

Dr. Peter (Peizhi) Luo, the founder and Chief Executive Officer of Adagene, is an experienced entrepreneur passionate on devising a sustainable biotechnology business strategy by leveraging the industry’s most advanced technology and intellectual property for novel product development. He utilizes a multi-disciplinary approach to his work, combining methods from experimental and computational biology, chemistry, and physics.

Prior to this, Dr. Luo was the Chief Technology Officer of Abmaxis Inc., a wholly owned subsidiary of Merck & Co., and Director of Biologics Technology at Merck & Co., Inc. Before the acquisition of Abmaxis by Merck in 2006, Dr. Luo was the Cofounder, Chief Technology Officer, President and a Board Director of Abmaxis Inc. During Dr. Luo’s time at Merck, he designed and built the antibody libraries and engineering platforms that propelled the discovery of Merck’s novel biologics. He received two Merck Special Achievement Awards for his leadership and scientific contribution. Before his work at Abmaxis, Dr. Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor. Through his work at Stanford, Dr. Luo discovered the fundamental mechanisms of protein folding and stability concerning the solvation of peptide backbone by cosolvents and amino acid side-chains.

Dr. Luo completed his postdoctoral research in protein folding with Dr. Robert L. Baldwin at Stanford University. He received his Ph.D. in chemistry under the guidance of Dr. David G. Lynn at The University of Chicago, M.S. degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences, and B.S. degree in applied chemistry from Peking University.

Xiaoyan Wang, PhD
MD /Partner IC Member

Dr. Xiaoyan Wang received her PhD in Biology from Chinese Academy of Sciences, and MBA from Shanghai Advanced Institution of Finance (SAIF) of Shanghai Jiao Tong University. She was a product specialist of genome analysis at Beckman Coulter, the Vice General Manager of Bioscience, the director of core facility in Shanghai Institute of Biochemistry and Cell Biology, the investment manager of China-Singapore Suzhou Industrial Park Venture Capital Co., Ltd., and the investment director of Oriza Seed Fund Management Co., Ltd.

During Dr. Wang’s tenure at China-Singapore Suzhou Industrial Park Venture Capital and Oriza Seed Fund Management Co., Ltd, she led the investments in early or developing stage companies in medical devices, pharmaceuticals and medical services. She was in charge of 9 investments, including Innovent Biologics, CF PharmaTech, Bowing Medical, Ryan Nano, Sealand Technology, Tennor Therapeutics, etc. most of these companies have completed the follow-up financing.

Dr. Wang has more than 10 years experience in medical industry, and years of experience in health industry equity investment. Now she is MD and partner of GP Healthcare Capital Co., Ltd.

F-Prime Capital Partners
http://fprimecapital.com/

F-Prime Capital is a global venture capital firm investing in life sciences, healthcare and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world's most significant challenges in healthcare and technology. Successful prior investments include Accuri, Adaptimmune, Blueprint Medicines, Ironwood, and Ultragenyx.

Eight Roads Ventures
http://www.eightroads.com

Eight Roads Ventures (formerly Fidelity Growth Partners) is the venture arm of Eight Roads, the proprietary investment arm of Fidelity International Limited. As a private venture capital investor, Eight Roads Ventures is dedicated to long-term investment approach on ventures specialized in Healthcare and Biosciences, and Technology. A strong track record includes investments in Alibaba, WuXi PharmaTech, Innovent, Hua Medicine, Hile, etc.

WuXi Corporate Venture Fund
http://www.wuxiapptec.com/

WuXi Corporate Venture Fund is an investment arm of WuXi PharmaTech, a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States.

GP Healthcare Capital
http://www.gpcapital.com.cn/

GP Healthcare Capital, a subsidiary fund of GP Capital, is a professionally managed private equity fund which invests in disruptive technology and products within the healthcare industry. Our mission is to provide capital to innovative organizations with visionary leadership teams who are challenging the status quo of medicine as it is practiced globally. We work closely with entrepreneurs to achieve our vision of a "Value Discoverer" and "Value Creator".

New World TMT
http://www.nwtmt.com/

New World TMT Ltd (NWTMT) is the telecom, media and technology business management arm of the New World Group, one of Hong Kong's blue chip conglomerates. Comprising three operational areas - Telecom, Media and Technology - NWTMT invests in and operates innovative enterprises in China and the Asia Pacific region.

Leon (Lianyong) Chen, Ph.D.

Dr. Chen is Founder and Managing Partner of Frontline BioVentures, boasting over 19 years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor.

He is a member of the Expert Review Panel for the Chinese Central Government HR’s 1000 Talent Plan, and an adviser to BioBAY of Suzhou Industrial Park. As a venture capital investor, his current and past affiliations include Fidelity Growth Partners-Asia (Partner) and BioVeda China (Managing Partner). Representative Investments include CITIC Pharmaceutical (Director of Board, Acting CFO), Cathay Industrial Biotechnology (Director of Board), Hile Biopharma (Director of Board), Hua Medicine (Shanghai) (Director of Board), Innovent Biologics Ltd (Chairman), Adagene (Director of Board) and MDDF (Director of Board).

While serving as a management consultant in the past, he worked at McKinsey & Company (Brussels), Ernst & Young (Palo Alto) and Life Science Strategic Consulting (Managing Partner, San Francisco Bay Area).

As a Ph.D. scientist, he worked with Schering Plough (New Jersey), and was a key member of the discovery team of Zytia / Vytorin - a multi-billion dollar drug. Dr. Chen was a Post-Doc at MIT, Ph.D. (with top honor) from the University of Louvain, Louvain-La-Neuve, B.S. from Peking University. He holds 6 issued US Patents, and is co-author of the 14th and 15th Ernst & Young Biotechnology Annual Report.

Wei Li, Ph.D.

Prior to joining Fidelity in 2005, Dr. Li focused his effort on healthcare and life science investment opportunities at Baird Venture Partners, the venture capital arm of R.W.Baird. Prior to Baird, he led drug discovery projects and technology licensing due diligence at Vertex Pharmaceuticals, a small-molecule therapeutic company based in Cambridge, MA. He also worked in strategic marketing at Serono International S.A., a biopharmaceutical company based in Geneva, Switzerland. During his scientific career, Wei first-authored numerous scientific publications in journals including Science, Proceedings of the National Academy of Sciences, and Journal of Biological Chemistry.

Wei received a B.S., with distinction, in Chemical Physics from University of Science and Technology of China, a Ph.D. in Biochemistry and Mammalian Genetics from Harvard University, and an MBA from the Kellogg School of Management at Northwestern University, where he was elected Beta Gamma Sigma, with a concentration in Finance, Accounting and Marketing. Dr. Li serves on the Board of Directors of TCT Medical and Innovent Biologics.

Mark P. de Souza, PhD

Mark P. de Souza, PhD is a serial entrepreneur, investor, and biotechnology consultant based in the San Francisco Bay area. He is passionate about developing first-in-class therapies for rare and neglected diseases with a high unmet medical need. He is a co-founder and member of the board of directors of NFlection Therapeutics , Myotherix, and ChromaDerm. He is a board member of Excelimmune.

Mark was formerly President and CEO of Lotus Tissue Repair and a member of its board of directors. Mark co-founded Lotus Tissue Repair in 2010 to develop recombinant collagen VII as protein replacement therapy for a devastating orphan genetic disease, dystrophic epidermolysis bullosa. Lotus Tissue Repair secured a $26 million Series A commitment from Third Rock Ventures in 2011. The company was acquired by Shire in early 2013.

Prior to founding Lotus, Mark was Vice President of Business Development at Dyax Corp, a biopharmaceutical company which discovered, developed and commercializes KALBITOR®, its lead product in hereditary angioedema, an orphan genetic disease. Since 2003, he led the business development team, which was responsible for licensing Dyax's phage display technology and products, including KALBITOR®, generating greater than $200 million in license fees and other forms of financing from 50+ antibody, protein, and peptide technology and product licensing transactions. Prior to joining Dyax, Mark conducted academic research at the University of California, Berkeley.

John Choi, MD-Ph.D.
Business development Advisor

Dr. John Choi is a Venture Partner at Fidelity Growth Partners Asia and Fidelity Biosciences, where he is responsible for Fidelity’s healthcare portfolio, which includes Adagene. Dr. Choi has extensive experience as a healthcare investor, and executive and serial entrepreneur. He is a co-founder of Hua Medicine, another Fidelity company, as well as Pytho Capital, a research-oriented, life-science specialized hedge fund that invests in small-cap, public biotech companies.

Before co-founding Pytho Capital, John was a Principal at the storied venture capital firm of Venrock Associates, the venture investing arm of the Rockefellers. During his tenure there, John focused on Venrock's biotechnology and medical device franchises, working actively with portfolio companies such as Coley Pharmaceuticals (acquired by Pfizer NYSE:PFE), Sirna Therapeutics (acquired by Merck NYSE: MRK), Celladon Corporation, and Princeton Lightwave. He was also previously involved with investments in Nanogram Devices Corporation (acquired by Wilson Greatbatch NYSE:GB), Targeted Genetics Corporation (NASDAQ:TGEN) and led the investment in Skinetics Biosciences (acquired by Sirna Therapeutics NASDAQ:RNAI). Prior to Venrock, he worked at the San Francisco offices of TVM Capital, an international venture capital firm with offices in the US and Europe.

Before embarking on his business and investment career, John worked in academia. He previously served as a Resident in the Departments of Internal Medicine and Genetics at Baylor College of Medicine. He completed his doctoral thesis at Harvard Medical School conducting nuclear magnetic resonance (NMR) studies of human T-cell surface proteins CD2 and CD4. In addition to his Ph.D. in Biophysics from Harvard University, John received his M.D. from Cornell University Medical College, and his B.S. in Applied Math and Physics from Yale College.